WO1995026198A1 - Metal complexes of aloe extracts for skin and hair - Google Patents
Metal complexes of aloe extracts for skin and hair Download PDFInfo
- Publication number
- WO1995026198A1 WO1995026198A1 PCT/US1995/003777 US9503777W WO9526198A1 WO 1995026198 A1 WO1995026198 A1 WO 1995026198A1 US 9503777 W US9503777 W US 9503777W WO 9526198 A1 WO9526198 A1 WO 9526198A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- copper
- gel
- composition
- ionic metal
- Prior art date
Links
- 235000011399 aloe vera Nutrition 0.000 title claims abstract description 111
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 61
- 239000002184 metal Substances 0.000 title claims abstract description 61
- 241001116389 Aloe Species 0.000 title claims description 43
- 239000000284 extract Substances 0.000 title description 8
- 210000004209 hair Anatomy 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 72
- 230000035876 healing Effects 0.000 claims abstract description 59
- 210000003491 skin Anatomy 0.000 claims abstract description 54
- 230000003779 hair growth Effects 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 32
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical class [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims abstract description 21
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 13
- 230000001965 increasing effect Effects 0.000 claims abstract description 10
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical class [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 55
- 206010052428 Wound Diseases 0.000 claims description 52
- 241001465754 Metazoa Species 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 8
- 230000007794 irritation Effects 0.000 claims description 7
- 206010040880 Skin irritation Diseases 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 150000004696 coordination complex Chemical class 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 230000036556 skin irritation Effects 0.000 claims description 4
- 231100000475 skin irritation Toxicity 0.000 claims description 4
- 206010072170 Skin wound Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000004792 oxidative damage Effects 0.000 claims description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 abstract description 69
- 208000002847 Surgical Wound Diseases 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 7
- 150000002739 metals Chemical class 0.000 abstract description 7
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 238000010668 complexation reaction Methods 0.000 abstract description 2
- 244000186892 Aloe vera Species 0.000 abstract 1
- 244000144927 Aloe barbadensis Species 0.000 description 69
- 239000000499 gel Substances 0.000 description 63
- 229910052802 copper Inorganic materials 0.000 description 28
- 239000010949 copper Substances 0.000 description 28
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 230000029663 wound healing Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 11
- 239000006072 paste Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 150000004699 copper complex Chemical class 0.000 description 7
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 6
- 229910001431 copper ion Inorganic materials 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001879 copper Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- -1 tryptophan or lysine Chemical class 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 208000028990 Skin injury Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- CMRVDFLZXRTMTH-UHFFFAOYSA-L copper;2-carboxyphenolate Chemical compound [Cu+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O CMRVDFLZXRTMTH-UHFFFAOYSA-L 0.000 description 4
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000009928 pasteurization Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 229940069521 aloe extract Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 229910052718 tin Inorganic materials 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- ADVPTQAUNPRNPO-REOHCLBHSA-N 3-sulfino-L-alanine Chemical compound OC(=O)[C@@H](N)C[S@@](O)=O ADVPTQAUNPRNPO-REOHCLBHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229910001369 Brass Inorganic materials 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 2
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- ADVPTQAUNPRNPO-UHFFFAOYSA-N alpha-amino-beta-sulfino-propionic acid Natural products OC(=O)C(N)CS(O)=O ADVPTQAUNPRNPO-UHFFFAOYSA-N 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000010951 brass Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229940124563 hair growth stimulant Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WZUMSFQGYWBRNX-AVGNSLFASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)CC1=CN=CN1 WZUMSFQGYWBRNX-AVGNSLFASA-N 0.000 description 1
- XUFUYOGWFZSHGE-UHFFFAOYSA-N 2-hydroxy-3,5-di(propan-2-yl)benzoic acid Chemical compound CC(C)C1=CC(C(C)C)=C(O)C(C(O)=O)=C1 XUFUYOGWFZSHGE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 241000230106 Aloe perryi Species 0.000 description 1
- 240000001518 Anchusa capensis Species 0.000 description 1
- 241000499316 Asphodelaceae Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000013270 Palmar hyperkeratosis Diseases 0.000 description 1
- 208000014417 Plantar hyperkeratosis Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 235000002594 Solanum nigrum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- WKIWEDKDZPIULI-XNTDXEJSSA-N chembl373277 Chemical compound OC1=CC=CC=C1\C=N\NC(=O)C1=CC=CC=C1 WKIWEDKDZPIULI-XNTDXEJSSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- SVOAENZIOKPANY-CVBJKYQLSA-L copper;(z)-octadec-9-enoate Chemical compound [Cu+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O SVOAENZIOKPANY-CVBJKYQLSA-L 0.000 description 1
- QUFKSSHMEXRJCK-UBKPKTQASA-L copper;3-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound [Cu+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O QUFKSSHMEXRJCK-UBKPKTQASA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 108010039747 glycyl-seryl-histidyl-lysine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 231100001067 mild skin irritation Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Definitions
- aloe gel-metal complexes in the case of wound healing, and the extent of decreased follicle size in the case of impaired hair growth, and the general state of health of the patient being treated, but will generally range from about 1 mg to about 25 mg per day of aloe gel-metal complex per day per square centimeter of wound site, with dosages of from about 5 mg to about 10 mg per day per square centimeter of wound site being more commonly used. Maintenance dosages over a prolonged period of time may be adjusted as necessary. For veterinary uses higher levels may be administered as necessary. Determining actual amounts of the aloe gel-metal complexes necessary to treat a particular wound or condition as described above will be through standard empirical methods well known in the art.
- This Example demonstrates the ability of aloe vera gel-copper complex to reduce inflammation associated with mild skin burns.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Methods are provided for preparing compositions suitable for protecting irritated or damaged skin from further oxidative and biochemical damage and thus permitting natural healing processes to progress, for accelerating the rate of healing of burns and surgical wounds, and for increasing the size of hair follicles and the rate of hair growth. The compositions generally comprise complexes formed by the complexation of aloe vera with ionic metals such as copper(II) salts and tin(II) salts.
Description
METAL COMPLEXES OF ALOE EXTRACTS FOR SKIN AND HAIR
Background of the Invention
Extracts from the plant aloe have a traditional use for the treatment of skin and skin injuries. Liquid obtained from the epidermis of leaves of Aloe forms a gel that can be applied to skin injuries and wounds. For ease of use, the aloe extract may be processed to a dry powder which can be subsequently restored to a gel form by the addition of water.
Controlled laboratory studies of the healing actions of the preferred aloe extract, commonly named aloe vera, however, provide a confusing picture of its preferred ability to stimulate the skin healing process. In these studies aloe vera gel has variously been reported to stimulate the skin healing process, to have no effect, or even to delay wound healing. For example, Rodriguez-Bigas et al., Plast.
Reconstr. Surq. 81: 386-389 (1988) , found aloe vera gel to accelerate the healing of full-thickness burns in guinea pigs. Similarly, Davis and Maro, J. Am. Podiatr. Med. Assoc. 79: 24-26 (1989) , reported aloe vera to improve wound healing in diabetic mice. On the other hand, Schmidt and Greenspoon,
Obstet. Gvnecol. 78: 115-117 (1991) reported aloe vera gel to delay the healing of women after cesarean delivery or laparotomy for gynecologic surgery from an average of 53 days using standard wound management techniques to an average of 83 days in women treated with aloe vera gel. Watcher and
Wheeland, J. Dermatol. Surq. Oncol. 15: 188-1195 (1989) found no beneficial effect of aloe vera gel on the healing of surgical wounds in pigs. Kaufman et al. , J. Burn Care Rehabil. 9: 156-159 (1988) , concluded that aloe vera gel hindered the healing process of second degree burn wound in guinea pigs. Bracken et al., J. Occup. Med. 27: 733-739 (1985) , found that aloe vera gel did not improve the healing of hydrofluoric acid burns in rats.
Currently, the general consensus seems to be that aloe vera extracts possess, at best, only a very mild healing action and are ineffective for the healing of more serious wound and injuries. The low efficacy and inconsistency of results with aloe vera gels has led to efforts to enhance a healing effect by various methods. Fulton, J. Dermatol. Surq. Oncol. 16: 460-467 (1990) , reported improved skin healing by using a stabilized aloe vera gel impregnated into a polyethylene oxide dressing. Davis et al., J. Am. Podiatr. Med. Assoc. 79:
559-562 (1989) , incorporated aloe vera gel into Eucerin cream and found improved healing of surgical wounds in rats.
Restoring the function of damaged and wounded skin continues to be a major health problem despite the development of various medications. Many approaches to skin-healing that are currently being developed, such as the production of growth factor proteins and pharmaceutical drugs with wound healing properties, and occlusive dressings for wounds, are beyond the economic reach of many patients. A major need exists for improved and low cost skin-care products and medicaments in less-developed countries, particularly in the tropics, where conditions such as inadequate health care, widespread skin fungal diseases, and the use of flammables such as kerosene for cooking and similar conditions give rise to high incidents of serious skin injury. For such countries, there is a critical need is to produce effective medicines that can be produced at very low cost using readily available materials. Even in more developed countries the increasing demands for cost-containment in medical services necessitate the development of low-cost products for skin care and pharmaceuticals for wound healing. Procedures such as hospitalization for the treatment of diabetic skin ulcers are increasingly being restricted. Thus, improved and cost- effective treatments for wound healing are required for the future.
Delayed healing or incomplete healing in humans and other animals causes additional pain and suffering for the patient and markedly increases wound complications and medical
costs. Often the wound continues as a chronic sore that requires extensive attention and medical care to control infection and tissue necrosis. Even when such wounds finally heal, the wound area is frequently devoid of the ability to respond to tactile stimulation and is often filled with excessive deposits of immature collagen that produces permanent scarring. The urgent need for improved wound- healing compositions extends to wounds generated by surgical procedures. The success of surgical procedures, especially in very ill or elderly patients, is typically a function of the adequacy and speed of post-surgical healing.
Another aspect that can impair the normal healing response is excessive inflammation of injured or wounded skin. While the inflammatory process and its concomitant influx of white cells into the afflicted area are an integral part of the natural healing process, in some cases the inflammatory process becomes excessive and delays healing. The wounded tissue becomes locked in an early phase of the healing process and cannot proceed to completion. In such instances, compounds with anti-inflammatory activities are used to allow the process to proceed normally. One promising approach for the therapeutic treatment of conditions associated with inflammation and impaired wound healing has been the use of metal ions complexed to organic molecules or amino acids, amino acid derivatives and peptides. Some of these complexes possess anti-inflammatory activity, while others possess both anti-inflammatory activity and healing actions. Yet other complexes reportedly possess hair-growth stimulating actions in addition to anti-inflammatory and/or healing activities, as described in, for example, applicant's co-owned pending patent application serial no. 07/954,620, which is incorporated in its entirety by reference herein.
The use of copper salts or complexes as anti- inflammatory agents for the healing of stomach ulcers in the treatment of patients suffering from acute or chronic arthritis dates back to the 1940's and 1950's (see, e.g., reviews by Sorenson, Inflammation. 3:317-331 (1976) ; Agents and Actions 8:305-331 (1981), and Comprehensive Therapy
11:49-64 (1985)). The use of copper salts and complexes, such as copper-salicylate complex, seems to have been abandoned, apparently due to the early promise of the steroidal anti- inflammatories, such as hydrocortisone. Other complexes of copper with amino acids (tryptophan, lysine) , with non- steroidal anti-inflammatory drugs (indomethacin, ketoprofen, acetylsalicylic acid) or with fatty acids (oleic, lauric and caprylic acids) have been studied but, despite their promise, were rarely developed beyond the preclinical phases, apparently due to problems of irritation, toxicity, and inadequate efficacy.
While many copper-complexes have been reported to possess anti-inflammatory properties, a more limited group have been reported to also possess healing actions. Heintze (U.S. Pat. No. 4,123,511) reported that a copper oleate complex had anti-inflammatory and skin healing activity. Sorenson (U.S. Pat. No. 4,440,754) describes the use of complexes of copper(II) salts and amino acids, such as tryptophan or lysine, or with organic molecules such as 3,5- diisopropylsalicylic acid, acetylsalicylic acid or salicylic acid, to prevent and heal gastrointestinal ulcers. Using a wound-healing model, Townsend and Sorenson (Sorenson et al., Agents and Actions 8:305-325 (1981)) found salicylate-copper to accelerate the rate of healing and to improve the quality of healing of surgically-induced ulcers in rats. Also,
Sorenson wrote (ibid, and Inflammation 3: 317-331 (1976)) that Townsend demonstrated that coppe (II)-(tryptophan)2 increased the rate of ulcer healing in a surgically-induced ulcer model. The increased healing was purportedly due to a more rapid re- epithelialization of the wound and an increase in the quantity and quality of the collagen. Fine collagen fibers in a normal orientation developed in treated animals, in contrast to non- treated animals in which the new collagen was very dense and composed of thick, wavy disoriented bundles, resembling scar tissue.
Federici and Bertolotto (EP 450,398 and IT 9,019,948) reports that chondroitin sulfate-copper(II) complexes possessed anti-inflammatory activity. European
Patent No. EP 66,283 discloses "eustatic" compositions which contain a non-toxic metal ion (including copper) and a glycosamino-glycan of hyaluronic acid or chondroitin sulfate useful as a cicatrizant (wound healing by closure) . UK Patent Application GB 2 044 265 describes metal complexes (including copper) of adenosine triphosphate as aiding the recovery of bone tissue in cases of fractures as well as in osteoporosis and bone cysts.
Konishi (US Pat. No. 4,461,724) reports that the tetrapeptide Gly-Ser-His-Lys and peptides of related structures possess anti-inflammatory and healing actions when complexed with metals such as ionic copper and zinc.
Yu (U.S. Patent 4,053,630) discloses the use of cysteic acid and its derivatives cysteine sulfinic acid or homocysteic acid, chelated to metal ions such as ferric, cupric, zinc or aluminum, to form compositions that alleviate symptoms of diseases characterized by defects of keratinization and achieved a remission of ichthyosis, dandruff and acne. Bertelli (U.S. Patent 4,156,737) suggests that copper complexes of p-aminomethyl-benzene-sulfonamide possess healing and protective effects on skin burns. Van Scott (U.S. Patent 4,283,386) reports that metallic (copper, zinc, or aluminum) salt forms of cysteic acid, cysteine sulfinic acid and homocysteic acid have therapeutic actions that produce remissions of dry and broken skin, keratoses, warts and palmar and plantar hyperkeratosis.
Niwa .Dermatoloqica 179 SI: 101-106 (1989)) and Bergren et al. (Am. Surq.. 54: 333-336 (1988)) found that the anti-inflammatory protein Cu, Zn-superoxide dismutase also acts to enhance healing processes.
Pickart (see, e.g., PCT Publications WO 91/14437, WO 91/12267, WO 91/05797, WO 91/03488, WO 89/12441, WO 88/26448, WO 88/08851, EP Patents EP 190,736, EP 189,182; and U.S. Pat. No. 4,767,753) describes the synthesis and use of metal complexes of Gly-L-His-L-Lys as anti-inflammatory and healing agents.
A number of metal complexes have been used to promote hair growth. Yamashiki (Japan Pat. 70018997) used a
complex of copper-pantothenate to purportedly promote growth of hair roots and promote skin functions. Morelle (U.K. Pat. GB 2097256, DE Pat. 32212448) used amino acid derivatives (N- butyryl amino acids) complexed with copper and other metals for cosmetic and therapeutic purposes, including use as hair and skin stimulants. Banfi et al. (U.S. Pat. No. 4,503,047) disclose a composition containing primarily one or more sulfur-containing amino acid(s) and copper(II) ions plus smaller amounts of allyl isothiocyanate and rhodanide ions to produce hair-growth stimulating actions. Pickart (e.g., WO 91/07431, 88/08695 and EP 288,278) found a number of metal complexes of derivatives of Gly-L-His-L-Lys to increase hair follicle size and the rate of hair-growth.
Despite the therapeutic promise of the above- mentioned metal complexes, toxicity and tissue irritation occur with many metal complexes (see, e.g., Johnson et al., Inorq. Chem. Acta. 67: 159-165 (1982); Pickart et al., Biochem. Pharm.. 32: 3868-3871 (1983); and Pickart et al., Lymphokines 8: 425-446 (1983)). For example, while copper- salicylate complexes and numerous copper-salicylate analogs possess anti-inflammatory activities, other salicylate analogs such as the copper(II) complex of salicylaldehyde benzoyl hydrazone are highly toxic to tissues. Similarly, copper(II)- Gly-L-His-L-Lys supports cellular viability and possesses anti-inflammatory and healing actions, yet close synthetic aroylhydrazone analogs of its copper-binding region are extremely toxic to cells and tissues.
Another problem with copper complexes for therapeutic use concerns the binding affinity of copper ion to the complexing molecule. While a defined copper-complex can be synthesized, its therapeutic use places the complex in the physiological milieu of the tissues where a plethora of literally hundreds of compounds compete for binding to the copper ion, which can form electrostatic bonds to as many as six separate molecules. If the copper is removed from the complex and becomes loosely bound, then tissue irritation occurs (see Raju et al., J. Natl. Cancer Inst.. 69: 1183-1188 (1982)) .
Further complications arise when such metal complexes are formulated into carrier creams or ointments. Various chemicals are added to the formulations to increase adherence to skin and wound surfaces and to enhance the penetration of the complexes into the target tissue. Yet, since many of these substances also bind to the metals, the expected therapeutic benefits may be nullified or significantly attenuated. Also, detergents such as sodium dodecyl sulfate are used to help blend oil and water phases of the emulsions and stabilize the formulations. However, such detergents are themselves tissue irritants that can delay healing.
Another problem encountered with many of the metal complexes intended for therapeutic use is that they cannot be heat-sterilized; hence, to meet safety requirements, high concentrations of antimicrobial chemicals must be added during manufacture to inhibit the growth of microorganisms and the transmission of viruses. These antimicrobial agents may also inhibit the viability and function of a host's cells such as macrophages and fibroblasts that are involved in the maintenance and repair of skin and other tissue, and thus these agents may retard the healing response.
What is needed in the art are compositions useful in tissue protection, tissue healing, and/or stimulating hair growth, which compositions could be conveniently produced and at low cost. Preferably, the compositions could be sterilized without loss of bioactivity and could be formulated for topical application without the use of detergents or other potentially irritating compounds. The ideal composition would also adhere well to skin and other materials such as wound dressings (for example, adhesive bandages) . To speed the time and expense required for regulatory approvals, the compositions would be prepared from materials that are generally recognized as safe by regulatory agencies and thus could be used with minimal safety concerns and regulatory barriers. Quite surprisingly, the current invention fulfills these and other related needs.
Summary of the Invention
The present invention provides compositions and methods for accelerating the healing of topical wounds and skin irritation, for protecting skin from damaging effects of oxidation, and for increasing the size of hair follicles and the rate of hair-growth in warm-blooded animals. The compositions useful in these methods, including pharmaceutical compositions, are prepared from an aloe gel, such as the gel extract of aloe vera, that is complexed with an ionic metal.
Thus, in one aspect the invention provides methods for preparing the pharmaceutical compositions useful in accelerating the healing of topical wounds or increasing hair follicle size and hair growth in a warm-blooded animal. An aloe gel is combined with an aqueous solution of a metal salt, then adjusted to an acceptable acidity range for skin products. Typically, the aloe gel is obtained as a dry powder from commercial sources then reconstituted into a gel with water. The aloe gel is then complexed to an ionic metal such as copper(II) , tin(II) , zinc(II) , etc. This procedure causes a very substantial and significant increase in the wound healing properties of an aloe gel and also produces compositions that markedly stimulate hair growth.
The resulting aqueous mixture is composed of complexes of the aloe gel and the metal ions. The amount of water in the mixture is adjusted to produce a thick but spreadable gel. The resultant gel may be used directly or combined with a pharmaceutically acceptable carrier to form a cream or lotion, in a concentration of from about 10% to about 50% aloe gel-ionic metal complex or more. The preparation may be pasteurized, if desired, without destroying the healing or hair growth stimulating activity of the aloe gel-metal complex.
In other embodiments the invention provides methods for enhancing the recovery of skin of a warm-blooded animal from wounds, such as surgical incisions, burns, inflammation or minor irritation due to oxidative damage, etc. The methods comprise administering to the skin wound or irritation a
therapeutically or, in some cases a prophylactically effective amount of a composition which comprises the aloe gel-ionic metal complex. Due to the gel-like composition of the invention, the material is particularly easy to apply to irregular surgical wounds and incisions.
Yet other embodiments relate to compositions and method for increasing hair follicle size and the rate of hair growth in warm-blooded animals, such as humans. The methods comprise administering to the skin in the area in which hair growth is desired an amount of aloe gel-ionic metal complex sufficient to increase hair follicle size and the rate of hair growth in said animal. The composition is administered in a variety of ways, such as topically in a gel or cream, by local injection, etc., and will be typically applied on a regular basis, e.g., daily, until hair growth is observed and for a time thereafter sufficient to maintain the desired amount of hair growth.
Description of the Specific Embodiments
Compositions and methods are provided by the present invention for topical skin treatments to protect damaged skin and thereby allow natural healing processes to proceed, to enhance tissue regenerative processes in the skin of warm blooded animals, and to stimulate hair growth in warm blooded animals. The composition are formed by the complexation of aloe gel and ionic metals such as copper, zinc, tin or the like. Methods are provided for improving the recovery of damaged skin, accelerating the healing of burns or surgical incisions, and stimulating hair growth in warm-blooded animals.
The aloe gel-ionic metal complexes of the present invention are prepared from aloe gel, or extracts from the leaves of plants which are members of the Aloe family (e.g., A. perryi , A. barbadensis, A. capensis and particularly Aloe vera) , or a dried aloe extract in a powdered form which can be
reconstituted. Aloe extracts, gels and powders are widely available from commercial sources.
To produce the aloe gel-ionic metal complexes useful in the present invention, the aloe gel, or the aloe powder which is converted to a gel by addition of water, is then complexed via admixture with one or more ionic metals, such as copper, zinc, indium or tin or the salts thereof, such as sulfate, acetate, phosphate, chloride, citrate, succinate, oxalate, cinnamate, tartrate, fumarate, maleate, glutarate, etc. By complexed is meant that the aloe gel and metal ions form electrostatic bonds, although this mechanism is offered by way of explanation only and not by way of limitation. In one method for preparing the aloe gel-metal complex, the aloe gel is mixed with sufficient water (generally at about room temperature, about 22-25°C) to form a thick gel. To obtain this gel, dry aloe powder (1 gram) is mixed with about 2 ml water. The gel is then mixed with a aqueous solution of an ionic metal salt, e.g., copper(II) chloride or tin(II) chloride, at a salt concentration of about 10 to 50% (w/v) , more preferably about 20% (w/v) . The volume of metal salt solution added is generally that amount needed to obtain a final metal concentration in the paste of from about 0.3% up to about 1.2% (weight/weight) or more. As the addition of the metal salt may reduce the pH of the gel, the pH of the gel is then raised to about 6.5. This pH is useful for skin preparations but other pH levels near neutrality or in the slightly acidic range are also efficacious.
The resultant thick gel can be applied directly to the skin or is formulated into skin creams and lotions at concentrations of usually 10 to 50% (w/w) although higher concentration are also effective.
The aloe gel-ionic metal complexes of the invention may be administered for a variety of therapeutic, prophylactic or cosmetic uses to humans or in veterinary applications to other warm-blooded animals. Among veterinary animals particularly well suited for treatment with the present compositions are species of equine, bovine, porcine, ovine, caprine, canine, avian, feline, etc.
The compositions and pharmaceutical preparations thereof are intended for local, topical, oral or parenteral (e.g. , subcutaneous injection) administration for prophylactic and/or therapeutic or cosmetic treatment. Preferably, the pharmaceutical compositions are administered locally, e.g., topically, as a paste, cream or salve.
For administration to warm-blooded animals, the aloe gel-ionic metal compositions will typically be sterilized and incorporated in pharmaceutical or veterinary formulations. Compositions which comprise the aloe gel-metal complexes can be sterilized by conventional, well known sterilization techniques, e.g., pasteurization, without substantially adversely affecting the biological activity of the aloe gel- ionic metal complexes. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions and as necessary to prepare compositions for convenient administration, such an pH adjusting and buffering agents, and delivery vehicles. Actual methods for preparing pharmaceutically administrable compounds will be known or apparent to those skilled in the art, some of which are described in detail in, for example, Remington's Pharmaceutical Science. Mack Publishing Co., Easton, PA pp. 428-429 (1981) , which is incorporated herein by reference.
Depending on the intended mode of administration and the intended use, the compositions may converted to solid, semi-solid, or liquid dosage forms, such, for example, as powders, granules, crystals, liquids, suspensions, liposomes, pastes, cremes, salves, etc. , and may be in unit-dosage forms suitable for administration of relatively precise dosages. The compositions may include a conventional pharmaceutical carrier or excipient and, in addition, may include other medicinal agents, growth factors, wound sealants, carriers, etc., as further described below.
For semi-solid compositions, as would be appropriate for pastes and creams intended for topical administration, the aloe gel-ionic metal complexes can be provided separately or may be compounded with conventional nontoxic carriers such as, for example, squalane, glycerol sterate, polyethylene glycol,
cetyl alcohol, stearic acid, and propylene glycol, among others. Such compositions may contain about 5-100% active ingredient, more preferably about 10-50%. The concentration of the aloe vera gel-ionic metal complexes in these formulations can vary widely, and will be selected primarily by intended use, viscosities, etc., in accordance with the particular mode of administration selected and intended treatment. The composition or formulation to be administered will, in any event, contain a quantity of the aloe gel-metal complexes sufficient to achieve the desired therapeutic or prophylactic effect in the subject being treated.
The tissue healing compositions of the invention are administered to a warm-blooded animal, such as humans, already suffering from a wound, oxidative skin damage, inflammatory skin lesions, as described above, in an amount sufficient to allow the healing process to proceed more quickly than if the host were not treated. In the case of an animal suffering from decreased hair follicle size and impaired hair growth, the compositions of the invention are administered in an amount sufficient to increase hair follicle size and the rate of hair growth. Amounts adequate to accomplish these effects are defined as a "therapeutically effective doses." Amounts effective for these uses will depend on the severity of the wound, sore, etc. , in the case of wound healing, and the extent of decreased follicle size in the case of impaired hair growth, and the general state of health of the patient being treated, but will generally range from about 1 mg to about 25 mg per day of aloe gel-metal complex per day per square centimeter of wound site, with dosages of from about 5 mg to about 10 mg per day per square centimeter of wound site being more commonly used. Maintenance dosages over a prolonged period of time may be adjusted as necessary. For veterinary uses higher levels may be administered as necessary. Determining actual amounts of the aloe gel-metal complexes necessary to treat a particular wound or condition as described above will be through standard empirical methods well known in the art.
In prophylactic applications compositions containing the aloe gel-ionic metal complexes are administered to a host susceptible to or otherwise at risk of skin lesions or similar damage, to enhance the host's own wound healing or anti- oxidative capabilities. Such an amount is defined to be a
"prophylactically effective dose." In this use, the precise amounts again depend on the host's condition and general state of health, but generally range from about 0.1 mg to about 10 mg per day per square centimeter of skin, more commonly from about 1 mg to about 3 mg per cm2 of skin per day. Single or multiple administrations of the compositions can be carried out.
The aloe gel-metal complexes of the invention may be administered in relatively large amounts without serious side effects, although indiscriminate use may produce discoloration of the skin. In instances where the compositions are administered to inhibit oxidative or biochemical damage to the skin or to those suffering from only mild irritation or inflammation of the skin, the dose may be adjusted accordingly to lower maintenance levels.
The compositions of the invention, including pharmaceutical compositions may be administered alone or as adjunct therapy or prophylaxis. The aloe vera gel-ionic metal compositions can be used in combination with other compositions, such as described in commonly owned copending US Patent 5,382,431 and patent applications USSN 08/218,392 and 08/219,681, each of which is incorporated herein by reference in its entirety, or with other growth factors known to improve other aspects of healing. In this manner, a synergistic effect may be attained that yields a clinical efficacy greater than that realized with any single factor. Further, while the compositions described herein stimulate a spectrum of healing processes, clinical wounds may differ considerably in their properties and healing patterns, leading one to utilize a combination of a composition described herein and another factor. For example, nerve regeneration is defective in many burns and thus one can add a specific nerve growth factor to supplement the composition to enhance nerve regrowth into the
burn area. Examples of factors with other reported healing properties include epidermal growth factor, fibroblast growth factor, nerve growth factor, transforming growth factors, angiogenic growth factors, heparin, fibronectin, fibrin, platelet-derived growth factor, enzymatic superoxide dismutase, extracts of blood or factors from the blood, and other similar factors.
The following examples are offered by way of illustration, not by way of limitation.
EXAMPLE I Preparation of Active Aloe Vera Gel-Ionic Metal Complexes
This Example describes methods used in the preparation of the aloe vera gel-ionic metal complexes having biological activities described further below. Aloe vera gel extract in a dry powdered form was purchased from Agro-Mar, Lakes, Nevada. Cupric chloride was from Sigma Chemical
Company, St. Louis, MO while tin (II) chloride, 99% pure was purchased from Aldrich Chemical Company, Milwaukee, WI.
In one method for preparing the aloe vera gel-ionic metal gel complex, the aloe vera gel was mixed with sufficient water (at room temperature, about 23 °C) to form a thick gel. To obtain this gel, dry aloe vera powder (1 gram) was mixed with 2 is water. The gel was then mixed with a aqueous solution of a metal salt (copper(II) chloride or tin(II) chloride at a salt concentration of 20% (w/v) . The volume of metal salt solution added is that amount needed to obtain a final metal concentration in the paste of 0.3 to 1.2% (weight/weight) . The addition of the metal salt reduced the pH of the gel to about 2.9. The pH of the gel was then raised to 6.5 by careful addition of 1 N sodium hydroxide. The aloe vera gel-copper complexes were used as skin protective agents that served as a skin barrier over damaged or irritated skin. The gel adhered to the skin and formed a protective barrier, while the complexed copper serves to
impart an antioxidant activity to the mixture. As shown below, damaged or irritated skin healed strikingly faster after treatment with such a composition.
As also described further below, the aloe vera gel- copper and aloe vera gel-tin were used to promote hair growth and the enlargement of hair follicles. In hair growth models in mice, application of these complexes to the skin produced a marked stimulation of hair growth after 8 to 12 days.
Other types of aloe vera gel-metal complexes, e.g., aloe from other plants, other salts of the metals, such as sulfate, acetate, phosphate, and so forth would be expected to work similarly.
EXAMPLE II
Healing of Surgical Wounds with Aloe Vera Gel-Copper Complexes
This Examples describes the use of a gel prepared with the aloe vera gel-copper complexes to hasten the healing of surgical incision wounds in animals.
Surgical incisions (1.25 cm) were made on the backs of anesthetized, 35 gram, Swiss-Webster mice. Immediately after surgery and 24 hours later, the wounds were covered with a thin film of the paste containing the active aloe vera gel-copper complex in Example I above.
Control wounds were untreated or were treated with aloe vera not containing the copper. As seen in Table 1, wounds treated with the active aloe vera gel-copper complex healed faster than control wounds. In contrast, aloe vera gel without copper ion had no significant healing action in this model.
Since rapidly healing wounds tends to contract and become more rounded, the healing activity can be related to the length of the wound after 9 days. Each group consisted of eight mice.
Table 1: Effect of aloe vera gel-copper complex on incision length.
Test group Length of wound after 9 days (cm.)
Control 0.87 + 0.15
Aloe vera gel- 0.90 ± 0.16 no copper
Aloe vera gel-
1.0% copper complex 0.46 ± 0.03 Aloe vera gel-
0.3% copper complex 0.54 + 0.10
EXAMPLE III Healing of Burn Wounds with Aloe Vera Gel-Copper Complex
This Example demonstrates the increased healing of burn wounds in animals using the aloe vera gel-copper compositions applied topically.
Second-degree burns were induced on the shaved backs on anesthetized mice by placing a circular (1.25 cm diameter, wound area = 1.22 cm2) brass rod (temperature 100°C) in contact the skin for 7 seconds. Immediately after burning, and 24 and 48 hours later, the wounds were covered with a thin film of the paste containing the active aloe vera gel-copper complex of Example I above. Control wounds were untreated or were treated with an aloe vera gel without copper. Wounds were traced on anesthetized mice, digitized from an computerized scanning bed, and area calculated from the computerized pixel number. Burns treated with the active aloe vera gel copper complexes showed less post-burn inflammation and healed markedly faster than untreated control wounds or wounds treated with an aloe vera gel without copper.
Table 2: Effect of aloe vera gel-copper complex on burn wounds.
Test group Area of wound after 15 days (cm2)
Control 0.85 ± 0.07
Aloe vera gel 0.79 ± 0.14 without copper
Aloe vera gel- 0.52 ± 0.08
0.3% copper complex Aloe vera gel- 0.46 ± 0.04
1.0% copper complex
EXAMPLE IV Reduction in Post-Burn Inflammation of Skin
This Example demonstrates the ability of aloe vera gel-copper complex to reduce inflammation associated with mild skin burns.
Very mild thermal burns were induced on the shaved backs of anesthetized mice (8 mice in each group) by a placing a circular (1.25 cm diameter, irritated area = 1.22 cm2) brass rod (60°C) in contact the skin for 5 seconds. This produced a mild skin irritation characterized by redness and swelling, but rarely a loss of skin tissue. Immediately after inducing the thermal injury, the irritated area was covered with a thin film of the gel containing one of the following: aloe vera gel without copper, aloe vera gel with 0.3% copper ion, aloe vera gel with 1.0% copper ion. Control wounds were untreated. Wounds were observed at daily intervals. At day 3, the untreated thermal injuries were still reddish and swollen while the skin with any of the three aloe vera gel-copper complexes had minimal reddishness and swelling. Aloe vera gel without copper gave a slight improvement in skin condition but much less than the copper-containing complexes.
EXAMPLE V Pasteurization of Active Aloe Vera Gel-Copper Composition
Pasteurization consists of heating a solution to
160° for 30 minutes which kills all but the hardiest microorganisms. For this test, various aloe vera gels were complexed with copper chloride by the methods described above in Example I. The resultant gels were then heated to 160°F for 30 min. After cooling to room temperature, the gels were applied to surgical incision wounds in mice in the manner described in Example II. Healing activity was similar to that observed with unpasteurized active composition, as shown in Table 3. Each group contained six mice.
Table 3: Effect of pasteurization on active complex.
Test group Length of wound after 9 days (cm)
Control 0.94 ± 0.10
Aloe vera gel 0.91 + 0. 14 no copper
Aloe vera gel-
1.0% copper complex 0.49 ± 0.11
Aloe vera gel- 0.3% copper complex 0.53 ± 0.11
EXAMPLE VI
Adherence of Aloe vera gel-Copper paste to Skin
This Example describes the use of a aloe vera gel- copper active complex to improve the adherence of a wound dressings to the surface of the skin. The aloe vera gel- copper complexes can thus be used to more effectively cover and seal wounds with dressings. Also, many tapes used to hold medical sensors to the skin or catheters in veins cause skin irritation. The incorporation of an aloe vera gel-copper
complex into the adhesive used on such tapes could reduce such skin irritation and injury.
For testing, the wound coverage area of a Band Aid™ brand adhesive bandage was cut away from the adhesive area. The wound coverage area of the tape, which has no skin adhesive qualities, was covered with the aloe vera gel with 0.3% copper ion. The paste-covered tape was applied to the upper arm of humans and left in place during normal work functions in an office. The tape adhered well to the skin during the subsequent 8 hour test. This demonstrates that such wound-healing pastes possessed significant adhesive properties on human skin.
EXAMPLE VII
Stimulation of Hair Growth
This Example describes the use of compositions containing aloe vera gel-copper complexes to stimulate the growth of hair follicles in warm blooded animals. The model used in this test was a mouse model that has been found to successfully predict the therapeutic response in humans (see, e.g., U.S. Pat. No. 5,118,665, which is incorporated herein by reference) . Hair growth in mammals proceeds through actively growing stages (anagen) followed by dormant stages (telogen) . The test method generally involved applying the hair growth stimulant to the skin of mice in telogen phase. Female, Swiss-Webster mice begin a telogen phase at about 45 days of age that lasts until about 90 days of age. After application of the active substance, enhanced hair growth is noted within 10 to 14 days. For this test, mice 50 days of age were used.
Aloe vera gel compositions containing copper(II) and tin(II) were tested. For testing, the aloe vera gel-metal pastes were mixed with saline (25% aloe vera gel composition and 75% physiological saline by weight) . Mice were shaved, then 0.05 ml of the mixture was infiltrated immediately below the skin by injection. Control mice were injected with an equal volume of saline. Each group contained 10 mice. After
12 days, the groups were compared. The percentage of mice with hair growth at the injection site and the relative strength of the hair growth response (on a scale of 1 to 5 where 1 is barely noticeable growth and 5 is very strong hair growth) were determined. The results, shown in Table 4, indicate that the compositions were active hair growth stimulants, with aloe vera gel-tin(II) complexes being the most effective agent.
Table 4: Stimulation of hair growth by Aloe vera gel-Metal
Complexes.
Percent with hair growth Average intensity at injection site of hair growth
Control mice 0 0
Aloe vera gel-no 0 0 copper(II)
Aloe vera gel-1% 100 2.0 copper(II) Aloe vera gel-1% 100 2.5 tin(II)
It is evident from the above results that the subject invention provides compositions of aloe vera gel-ionic metal complexes for topical skin, wound and surgical treatments to protect damaged skin and facilitate natural healing processes, to enhance tissue regenerative processes in the epidermis, and to stimulate hair growth in warm blooded animals. The invention also provides economical methods for preparing and formulating the compositions for topical administration.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain
changes and modifications may be practiced within the scope of the appended claims.
Claims
1. A method for accelerating the healing of topical wounds in a warm-blooded animal which comprises: administering to the wound a therapeutically effective amount of a composition which comprises an aloe gel complexed with an ionic metal.
2. The method of claim 1, wherein the ionic metal is copper(II) , and therapeutically acceptable salts thereof.
3. A method for enhancing the recovery of skin of a warm-blooded animal from irritation, comprising: administering to the skin irritation a therapeutically effective amount of a composition which comprises an aloe gel complexed with an ionic metal.
4. The method of claim 3 where the ionic metal is copper(II) .
5. A method for protecting the skin from oxidative damage and aiding the recovery of skin wounds in a warm blooded animal, comprising: administering to the skin or wound site a prophylactically or therapeutically effective amount of a composition which comprises a aloe gel complexed with an ionic metal.
6. The method of claim 5, wherein the ionic metal is copper(II) , and therapeutically acceptable salts thereof.
7. A method for increasing hair follicle size and the rate of hair growth in a warm-blooded animal, comprising: administering to the skin of said animal a composition which comprises a aloe gel complexed with an ionic metal in an amount sufficient to increase hair follicle size and the rate of hair growth in said animal.
8. The method of claim 7, wherein the composition is administered by injection into the skin.
9. The method of claim 7, wherein the ionic metal is copper(II) or tin(II) , and therapeutically acceptable salts thereof.
10. The method of claim 9, wherein the ionic metal is tin(II) .
11. A composition useful for accelerating the healing of topical wounds of a warm-blooded animal which comprises a therapeutically effective amount of a aloe gel complexed with an ionic metal.
12. The composition of claim 11, wherein the ionic metal is copper(II) or tin(II) , and therapeutically acceptable salts thereof.
13. The composition of claim 11, wherein the ionic metal is copper(II) .
14. The composition of claim 11, further comprising a pharmaceutically acceptable carrier.
15. The composition of claim 11, wherein the aloe gel-metal complex is present at a concentration of 10% to 50%.
16. A pharmaceutical composition for increasing hair follicle size and rate of hair growth in a warm-blooded animal, which comprises a hair growth stimulating amount of a aloe gel-ionic metal complex and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16, wherein the aloe gel-ionic metal complex is present in the composition at a concentration of 10% to 50%.
18. The pharmaceutical composition of claim 16, wherein the ionic metal is copper(II) or tin(II), and therapeutically acceptable salts thereof.
19. The pharmaceutical composition of claim 16, which is formulated for topical administration.
20. The pharmaceutical composition of claim 16, which has been sterilized by heating or pasteurized.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21961/95A AU2196195A (en) | 1994-03-28 | 1995-03-27 | Metal complexes of aloe extracts for skin and hair |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21904794A | 1994-03-28 | 1994-03-28 | |
US08/219,047 | 1994-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995026198A1 true WO1995026198A1 (en) | 1995-10-05 |
Family
ID=22817623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/003777 WO1995026198A1 (en) | 1994-03-28 | 1995-03-27 | Metal complexes of aloe extracts for skin and hair |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2196195A (en) |
WO (1) | WO1995026198A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0801554A1 (en) * | 1994-12-21 | 1997-10-22 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US7404967B2 (en) | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
WO2011069184A1 (en) * | 2009-12-08 | 2011-06-16 | Dynamiclear Pty Ltd | Composition for treating skin lesions |
US8828941B2 (en) | 2007-02-23 | 2014-09-09 | Divya Diwan | Composition and method for the treatment or prevention of spinal disorders |
WO2015114181A1 (en) | 2014-01-30 | 2015-08-06 | Tello De Juan Maria Del Mar | Cold natural aloe vera gel without stabilisers |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4465629A (en) * | 1983-03-17 | 1984-08-14 | Maughan Rex G | Method to increase color fastness of stabilized aloe vera |
US4708873A (en) * | 1986-01-29 | 1987-11-24 | Schulte Thomas L | Method of chemically debriding uncerated necrotic tissue |
US4877770A (en) * | 1985-02-08 | 1989-10-31 | Procyte Corporation | Chemical derivatives of GHL-Cu |
US5164367A (en) * | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
US5294434A (en) * | 1991-04-22 | 1994-03-15 | King Ronald M | Aloe vera gel toothpaste |
US5382431A (en) * | 1992-09-29 | 1995-01-17 | Skin Biology, Inc. | Tissue protective and regenerative compositions |
-
1995
- 1995-03-27 WO PCT/US1995/003777 patent/WO1995026198A1/en active Application Filing
- 1995-03-27 AU AU21961/95A patent/AU2196195A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4465629A (en) * | 1983-03-17 | 1984-08-14 | Maughan Rex G | Method to increase color fastness of stabilized aloe vera |
US4877770A (en) * | 1985-02-08 | 1989-10-31 | Procyte Corporation | Chemical derivatives of GHL-Cu |
US4708873A (en) * | 1986-01-29 | 1987-11-24 | Schulte Thomas L | Method of chemically debriding uncerated necrotic tissue |
US5164367A (en) * | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
US5294434A (en) * | 1991-04-22 | 1994-03-15 | King Ronald M | Aloe vera gel toothpaste |
US5382431A (en) * | 1992-09-29 | 1995-01-17 | Skin Biology, Inc. | Tissue protective and regenerative compositions |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0801554A1 (en) * | 1994-12-21 | 1997-10-22 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
EP0801554A4 (en) * | 1994-12-21 | 2000-03-29 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US6455076B1 (en) | 1994-12-21 | 2002-09-24 | Gary S. Hahn | Formulations and methods for reducing skin irritation |
US7404967B2 (en) | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
US8147855B2 (en) | 1994-12-21 | 2012-04-03 | Cosmederm Bioscience, Inc. | Methods for inhibiting sensory responses in the skin such as pain and itch using topical product formulations containing strontium |
US8449923B2 (en) | 1994-12-21 | 2013-05-28 | Cosmederm Bioscience, Inc. | Methods for inhibiting sensory nerves by topically administering strontium-containing compositions to keratinized skin |
US8828941B2 (en) | 2007-02-23 | 2014-09-09 | Divya Diwan | Composition and method for the treatment or prevention of spinal disorders |
US9480819B2 (en) | 2007-02-23 | 2016-11-01 | Divya Diwan | Composition and method for the treatment or prevention of spinal disorders |
US10322166B2 (en) | 2007-02-23 | 2019-06-18 | Kunovus Pty Ltd | Composition and method for the treatment or prevention of spinal disorders |
WO2011069184A1 (en) * | 2009-12-08 | 2011-06-16 | Dynamiclear Pty Ltd | Composition for treating skin lesions |
WO2015114181A1 (en) | 2014-01-30 | 2015-08-06 | Tello De Juan Maria Del Mar | Cold natural aloe vera gel without stabilisers |
Also Published As
Publication number | Publication date |
---|---|
AU2196195A (en) | 1995-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5382431A (en) | Tissue protective and regenerative compositions | |
US5888522A (en) | Tissue protective and regenerative compositions | |
US5858993A (en) | Starch-metal complexes for skin and hair | |
MXPA96004387A (en) | Complexes metal starch for skin and head | |
US5529987A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
US8183204B2 (en) | Methods and compositions for increasing skin remodeling | |
CA1286988C (en) | Use of ghl-cu as a wound-healing and anti-inflammatory agent | |
JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
US5550112A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
US5420114A (en) | Methods for the treatment of skin disorders | |
WO1995026198A1 (en) | Metal complexes of aloe extracts for skin and hair | |
AU709422B2 (en) | Method for topical treatment of scar tissue and related tissue reaction to trauma | |
US5616619A (en) | Topical composition for burn relief and method of use | |
US20050276766A1 (en) | Methods and compositions for increasing skin remodeling | |
WO1995026194A1 (en) | Allantoin-metal complexes for skin and hair | |
CA2126704C (en) | Dermatological compositions and methods for the treatment of skin therewith | |
CA2256093C (en) | Topical pharmaceutical compositions for healing wounds | |
AU687840B2 (en) | Topical composition for burn relief and method of use | |
MXPA00005595A (en) | Topical zinc compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |